Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending January 2016. The report serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibilities (PDMRs) in accordance with DTR 3.1.4R(1)(a).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of insider share acquisitions rather than a financial performance report.
Material Changes
No material changes to financial performance or operations are reported in this filing. The document details a specific transaction event where multiple directors acquired shares through the GSK ShareReward Plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It strictly reports on the acquisition of shares by PDMRs on January 12, 2016, at a price of 1359.14 pence per Ordinary Share.
Important Facts for Investors
- Transaction Date: Shares were acquired on January 12, 2016.
- Share Price: 1359.14 pence per Ordinary Share.
- Participants: Ten Directors/PDMRs participated, including Sir Andrew Witty, Mr R G Connor, Mr S Dingemans, Mr N Hirons, Mr D S Redfern, Ms C Thomas, Mr P C Thomson, Dr P J T Vallance, Ms E Walmsley, and Mrs V A Whyte.
- Acquisition Volume: Each participant acquired 9 shares under the personal contribution element and 9 shares under the matching element (GSK contribution) of the ShareReward Plan.
- Signatory: The report was signed by Victoria Whyte, Company Secretary, on January 13, 2016.